

# MARKET INSIGHT

APRIL 2012

WEALTH MANAGEMENT



# Market analysis

INSIGHT - APRIL 2012

## Global economic conditions

### Are concerns about huge swings in international equity markets still justified?

Stock markets have rallied strongly since the lows of September 2011, particularly in Europe and the US. In the wake of the recess underway since mid-March, should we be concerned about a fresh wave of risk aversion, comparable to that of summer 2011?

For the past three years, our favoured scenario has been based on a transitional economic cycle in the shape of a *square root*. After the downturn in 2008-2009, followed by a sharp recovery in 2010, the world economy has entered a period of swift and successive acceleration and deceleration in activity. Weaker expansion than in the 2000s and a high degree of economic

Liquidity injections by the ECB in December 2011 and February 2012 were undoubtedly an important factor behind the stock market rally since December. This action by the monetary authority was necessary to allay concerns about a fresh global recession triggered by the European crisis. But this does not mean that macroeconomic doubts are a thing of the past, and it would be going too far to assume that risk aversion phases will not make a come-back.

That said, it is likely that liquidity injections into the European financial system will prevent any financial market turmoil from reaching the same magnitude as in the summer of 2011.

« Should we be concerned about a fresh wave of risk aversion, comparable to that of summer 2011? »

**FRANÇOIS SAVARY**, CHIEF INVESTMENT OFFICER, REYL & CIE

volatility are the assumptions underlying this vision.

The logical counterpart of the economic cycle's weaker visibility is highly volatile financial markets. Unlike in the cycles of 1990 to 2007, the great uncertainty about economic developments is fueling erratic movements in investor psychology. Sometimes the fear of a dip back into a global recession heightens risk aversion and sends equities down, at other times a series of more positive economic indicators generates excessive enthusiasm for risky assets. This demonstrates that markets no longer know which way to turn.



While the premise of a linear performance by equities in the near future appears incompatible with our economic views, the risks of a significant correction by equity markets are more reduced.

Investors must continue to adopt a tactical investment policy and adjust their allocation depending on how the ongoing cycles of aversion/love towards risk may unfold. However, as a result of liquidity injections in recent months, any downturns

in the equity markets should take the form of a consolidation. This implies that investors should not be too greedy when seeking an entry point into equities.

## Focus

# “ Food: a growth sector? ”



**DANIEL STECK**  
Financial analyst in charge of Reyl Group's North American Equities selection.

Despite the sector's primarily defensive appeal, pockets of growth still exist.

### In which areas can growth be found in the food sector?

Investors are generally interested in the sector's defensive characteristics, more than in its strong earnings growth. However, some specialised sub-segments, such as infant nutrition have particularly attractive growth potential. This relatively fragmented US\$26 billion market is growing by around 8% annually and could be worth US\$36 billion by 2016.

### What are the principal growth drivers of specialist nutrition for children and babies?

Emerging markets are fuelling growth in this segment. Rapid urbanisation in these countries is bringing about behavioural changes among consumers, who are turning to specialised nutritional products for their children. And GDP growth, which is closely correlated with birth rates, is far stronger in emerging countries than in developed markets.


### Who are the principal operators in this segment?

All leading consumer companies are present in this sector, whether European or US based, Nestlé, Danone and Heinz generate a significant share of their revenues via this sector. US healthcare groups, such as Pfizer or Abbott, also have a foothold in this business which, like pharmaceuticals, requires considerable investment in areas of research and development. However, the global market leader is Mead Johnson, which is the only *pure play* company in this sector.

## IN A NUTSHELL

A defensive way to gain exposure to emerging markets

With just over 10% of market share Mead Johnson is the market leader. The group generates 66% of its sales and 72% of its profits in developing countries, and China is the leading company's growth contributor. In 2011, sales in China increased by 45%.



— Mead Johnson Nutrition CO

Over the next five years, annual earnings growth could average 12%. The stock, while expensive, is an excellent way to gain exposure to China through a defensive investment.

Mead Johnson is one of our favourite stocks in the consumer staples sector.



●

## INVESTMENT TEAM

**François Savary** - CHIEF INVESTMENT OFFICER

**Cédric Özazman** - EUROPEAN EQUITIES & ADVISORY  
coz@reyl.com TEL. : +41 22 816 81 64

**Daniel Steck** - NORTH AMERICAN EQUITIES

**Luc Filip** - FUNDS SELECTION

**Nicolas Roth** - ADVISORY HEDGE FUNDS

**Hasan Aslan** - ADVISORY HEDGE FUNDS

**Kinan Khadam-Al-Jame** - STRUCTURED PRODUCTS

**Daniel Racine** - DISCRETIONARY MANAGEMENT

**Sales Bischofberger** - SENIOR RELATIONSHIP MANAGER, REYL ZURICH

**Daryl Liew** - HEAD OF PORTFOLIO MANAGEMENT, REYL SINGAPORE

**Inglina Juvalta** - MANAGEMENT ASSISTANT  
iju@reyl.com TEL. : +41 22 816 81 44

●

[www.reyl.com](http://www.reyl.com)

●

●

## IMPORTANT INFORMATION

This content is being provided by Reyl & Cie Holding SA or/and its affiliates (hereinafter referred to as "REYL") solely for information purposes, it shall be intended for internal use strictly and is not intended to be a solicitation or offer, recommendation or advice to buy or sell interests in any security or investment product mentioned in it, to effect any transaction, or to conclude any transaction of any kind whatsoever, in particular to any recipient who is not a qualified, accredited, eligible or / and professional investor. It is intended for the sole use of the recipient and may not be forwarded, printed, downloaded, used or reproduced for any other purpose. Whilst REYL shall use reasonable efforts to obtain information from sources which it believes to be reliable, REYL, its directors, officers, employees, agents or shareholders assume no liability regarding this content and gives no warranty as to the accuracy, completeness or reliability of any mentioned data and thus assumes no liability for losses arising from the use of this content. This content is intended only for recipient who understand and are capable of assuming all risks involved. Before entering into any transaction, the recipient should determine if the relevant security or investment production mentioned in the content suits his particular circumstances and should ensure that the independently assesses (together with his professional advisers) the specific risks, the legal, tax, accounting consequences and eligibility requirements of any purchase of securities or investment products mentioned in the content. REYL makes no representation as to the suitability of the mentioned information, opinions or securities and investment products. Historical data on the performance of the securities and investment products or the underlying assets are no indication for future performance. The present content has been compiled by a department of REYL which is not an organisational unit responsible for financial research. REYL is subject to distinct regulatory requirements and certain securities and investment products may not be available in all jurisdictions or to all recipient types. The recipient should therefore comply with its local regulations. There is no intention to offer securities or investment products in countries or jurisdictions where such offer would be unlawful under the relevant domestic law.

●